Home > Insider Trading > Filing (0001209191-19-001588)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567514	Intra-Cellular Therapies Inc.	ITCI	Pharmaceutical Preparations (2834)	364742850

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1585669	E. Kimberly Vanover	C/O Intra-Cellular Therapies, Inc. 430 East 29Th Street New York NY 10016	Svp, Early Stage Clinical Dev.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-12-31	9,322	$0.00	21,695	No	4	A	Direct
Common Stock	Disposition	2019-01-02	4,834	$11.10	16,861	No	4	S	Direct
Common Stock	Acquisiton	2019-01-03	2,649	$0.00	19,510	No	4	M	Direct
Common Stock	Acquisiton	2019-01-03	16,160	$0.00	35,670	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2019-01-03	2,649	$0.00	2,649	$0.00
Common Stock	Restricted Stock Units	Disposition	2019-01-03	16,160	$0.00	16,160	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,649			No	4	M	Direct
32,320			No	4	M	Direct

Footnotes

Represents shares issued upon the vesting of performance stock units.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2018. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of performance stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Restricted stock units convert into common stock on a one-for-one basis.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On January 3, 2017, the reporting person was granted 7,946 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.